1. J.N. Ingle, P.A. Johnson, V.J. Suman, J.B. Gerstner, J.A. Mailliard, J.K. Camoriano, D.H. Gesme Jr., C.L. Loprinzi, A.K. Hatfield, L.C. Hartmann, A randomized Phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer Interdiscip. Int. J. Am. Cancer Soc. 80, 218–224 (1997)
2. T. Iveson, I. Smith, J. Ahern, D. Smithers, P. Trunet, M. Dowsett, Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res. 53, 266–270 (1993)
3. N.K. Ibrahim, A.U. Buzdar, Aromatase inhibitors: current status. Am. J. Clin. Oncol. 18, 407–417 (1995)
4. H.J. Burstein, J.J. Griggs, A.A. Prestrud, S. Temin, American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor–positive breast cancer. J. Oncol. Pract. 6, 243–246 (2010)
5. K. Wasan, P. Goss, P.H. Pritchard, L. Shepherd, M. Palmer, S. Liu, D. Tu, J. Ingle, M. Heath, D. Deangelis, The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA. 17L). Ann. Oncol. 16, 707–715 (2005)